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Introduction/Objective: Recent evidence suggests that abnormalities involving Th17 lympho-
cytes are associated with the pathophysiology of systemic lupus erythematosus (SLE). In
addition, multifunctional T cells (MFT), i.e., those producing multiple cytokines simulta-
neously, are present in the inﬂammatory milieu and may be implicated in the autoimmune
process observed in SLE. In the present study, we aimed to characterize the functional status
of  CD4+ T cells in SLE by simultaneously determining the concentration of IL-2, IFN- and
IL-17 in lymphocyte cultures under exogenous and self-antigenic stimuli.
Patients and methods: Eighteen patients with active disease, 18 with inactive disease, and 14
healthy controls had functional status of CD4+ T cells analyzed.
Results: We found that SLE patients presented a decreased number of total CD4+ cells, an
increased number of activated T cells, and an increased frequency of Th17 cells compared
to  healthy controls (HC). MFT cells had increased frequency in SLE patients and there was an
increased frequency of tri-functional MFT in patients with active SLE compared with those
with  inactive SLE. Interestingly, MTF cells produced larger amounts of IFN than mono-
functional T cells in patients and controls.
Conclusion: Taken together these data indicate the participation of recently activated Th17
cells  and MTF cells in the SLE pathophysiology.
© 2015 Elsevier Editora Ltda. All rights reserved.
Linfócitos  Th17  e  linfócitos  T  CD4+ multifuncionais  em  pacientes
com  lúpus  eritematoso  sistêmico
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Lúpus eritematoso sistêmico
Linfócitos T
Introduc¸ão/Objetivo: Evidências recentes sugerem que anormalidades que envolvem os lin-
fócitos Th17 estão associadas à ﬁsiopatologia do lúpus eritematoso sistêmico (LES). Além
disso, os linfócitos T multifuncionais (LTM), ou seja, aqueles que produzem múltiplas
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citocinas simultaneamente, estão presentes no meio inﬂamatório e podem estar implicados
no  processo autoimune observado no LES. No presente estudo, objetiva-se caracterizar o
estado funcional dos linfócitos T CD4+ no LES e determinar simultaneamente a concentrac¸ão
de IL-2, IFN- e IL-17 em culturas de linfócitos sob estímulos exógenos e autoantigênicos.
Pacientes e métodos: Dezoito pacientes com doenc¸a ativa, 18 com doenc¸a inativa e 14 controles
saudáveis foram submetidos à análise do estado funcional dos linfócitos T CD4+.
Resultados: Encontrou-se que os pacientes com LES apresentaram uma diminuic¸ão na quan-
tidade total de células CD4+, um aumento na quantidade de linfócitos T ativados e um
aumento na frequência de linfócitos Th17 em comparac¸ão com controles saudáveis (HC).
As  células LTM tinha frequência aumentada em pacientes com LES e houve um aumento na
frequência de LTM trifuncionais em pacientes com LES ativo em comparac¸ão com aqueles
com  LES inativo. Curiosamente, as células MTF produziram quantidades maiores de IFN-
do  que os linfócitos T monofuncionais em pacientes e controles.
Conclusão: Analisados em conjunto, esses dados indicam a participac¸ão dos linfócitos Th17
recentemente ativados e células MTF na ﬁsiopatologia do LES.
©  2015 Elsevier Editora Ltda. Todos os direitos reservados.
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ffector CD4+ T cells have been initially categorized into
wo subsets based on the cytokines they produce.1–3 Th17
ells are part of this new T cell scenario and display an
ctivated CD4+ T cell phenotype characterized by the pro-
uction of high amounts of IL-17.4–6 Th17 cells seem to
lay a crucial role in the development of a wide range of
utoimmune and chronic inﬂammatory disorders.7–9 In fact,
t has been suggested that inappropriate regulation of Th17
ells may be a key event in the pathogenesis of rheuma-
oid arthritis and systemic lupus erythematosus (SLE).10–14
everal studies reported signiﬁcantly higher serum levels
f IL-17 and higher frequency of IL-17-producing peripheral
lood mononuclear cells (PBMC) in SLE patients as com-
ared to normal individuals.13,15–18 It was also shown that
h17 response is correlated with disease activity in SLE
atients.17
A novel strategy for the evaluation of T cell functional-
ty is based on the simultaneous determination of several
ytokines expressed by subtypes of cells. According to this
pproach T cells that produce multiple cytokines simulta-
eously are termed multifunctional T cells. Multifunctional
 cell responses have been documented in HIV-119 and in
he immune response to vaccination against Hepatitis B
irus20 and HIV.19,20 This novel approach has been largely
ossible due to technological advances in ﬂow cytometry
hat nowadays allows for the simultaneous detection of
umerous functional, phenotypic, and lineage markers on T
ells.21
In the present study, we  sought to further characterize the
unctional status of CD4+ T cells in SLE patients with active
nd inactive diseases by simultaneously determining the con-
entration of several cytokines in lymphocyte cultures under
ifferent antigenic stimuli. We also quantiﬁed the propor-
ion of Th17 and multifunctional T cells and correlated them
ith SLEDAI (Systemic Lupus Erythematosus Disease Activity
ndex), and with the frequency of activated T cells and TREG
ells.Materials  and  methods
Thirty-six adult patients (33 women and 3 men, aged 40 ±
7.2 years) with a diagnosis of SLE based on the American Col-
lege of Rheumatology criteria22 were consecutively enrolled in
the study after providing informed consent. All patients were
referred from the outpatient clinic at the Division of Rheuma-
tology of the Universidade Federal de São Paulo (Federal
University of São Paulo). Patients were divided into two  groups
based on their SLE Disease Activity Index (SLEDAI) score.23,24
The active SLE group (A-SLE) comprised 18 patients (SLEDAI
score ≥6; 17 women and 1 man, aged 36.7 ± 10.2 years) and
the inactive SLE group (I-SLE) comprised 18 patients (SLEDAI
score = 0; 16 women and 2 men, aged 39.2 ± 13.9 years). Table 1
depicts the demographic and clinical characteristics of all
patients enrolled in the study. As a control, 14 healthy labora-
tory workers were enrolled in the study (13 women and 1 man,
aged 33.9 ± 10.4 years) after giving informed consent. Patients
and healthy controls underwent a structured questionnaire
and donated 60 mL  of venous blood. The study protocol was
reviewed and approved by the institution’s research ethics
committee.
Peripheral blood mononuclear cells (PBMC) were isolated
by density-gradient sedimentation over Ficoll–Paque (Pharma-
cia Biotech, Uppsala, Sweden) and washed twice in Hank’s
balanced salt solution (Gibco, Grand Island, NY). For cryo-
preservation, cells were slowly frozen in 90% of fetal bovine
serum (FBS; HyClone Laboratories, Logan, UT), and stored in
liquid nitrogen. At the time of the assay, PBMC were rapidly
thawed in a 37 ◦C water bath and washed in pre-heated RPMI
1640 supplemented with 10% fetal calf serum, 100 U/mL  peni-
cillin, 100 g/mL streptomycin and 20 mM glutamine (R10).
Cells were counted, checked for viability, and suspended in
R10 at a concentration of 1 × 106 viable cells/mL.
Thawed PBMC were incubated in 96-well plates
(200 l/well) (Becton Dickinson, San Jose, CA) in the pres-
ence of 100 ng/mL phorbol 12-myristate 13-acetate (PMA;
Sigma) and 500 ng/mL ionomycin or with 100 ng/mL HEp-2
extract for 16 h. After stimulation, cells were centrifuged at
30  r e v b r a s r e u m a t o l . 2 0 1 6;5 6(1):28–36
Table 1 – Demographic characteristics of controls and patients with systemic lupus erythematosus.
Controls (n = 14) A-SLE (n = 18) I-SLE (n = 18) p Value
Age 33.9 ± 10.4 36.7 ± 10.2 39.2 ± 13.9 0.624
Female (%) 92.8% 94.4% 88.9% 0.987
SD, standard deviation; A-SLE, active systemic lupus erythematosus; I-SLE, inactive systemic lupus erythematosus; SLEDAI, systemic lupus
erythematosus disease activity index; ns, not signiﬁcant.
1500 g for 5 min, suspended in Macs buffer and transferred
into V-bottom 96-well plates (Nunc, Roskilde, Denmark) in
100 L of staining buffer [phosphate-buffered saline (PBS)
supplemented with 0.1% sodium azide (Sigma) and 1% FBS,
pH 7.4] with the panel of surface monoclonal antibodies
(CD4–PerCP, CD3–APC-CY7 and CD69–PE-Cy7). Cells were
incubated at 4 ◦C in the dark for 30 min, washed twice with
PBS and then suspended in 100 L of ﬁxation buffer [1%
paraformaldehyde (Polysciences, Warrington, PA) in PBS, pH
7.4]. For intracellular staining, cells already labeled for surface
markers were incubated with 100 L of 4% ﬁxation buffer and
washed with permeabilization buffer (PBS supplemented with
0.1% sodium azide, 1% FBS and 0.1% saponin; Sigma). Each
sample was suspended in 100 L of permeabilization buffer,
incubated for 15 min  at room temperature in the dark, washed
with 100 L of staining buffer and incubated for 30 min  at 4 ◦C
in the dark with either no antibody (unstained tube) or with
a pool of anti-IL-2–PE, anti-IFN-–APC, and anti-IL-17–FITC
monoclonal antibodies in 50 L of staining buffer.25 Cells
were washed with 200 L of staining buffer and suspended in
100 L of freshly prepared 1% paraformaldehyde (PFA) pH 7.4.
TREG cells and effector CD25+ T cells were identiﬁed
according to a previously established protocol.26 Brieﬂy,
PBMCs were washed in PBS and 0.5 × 106 viable cells
were incubated with ﬂuorescein isothiocyanate (FITC)-labeled
anti-CD127, allophycocyanin-Cy3 (APC-Cy3)-labeled anti-CD3,
PerCP-labeled anti-CD4, and phycoerythrin (PE)-Cy7-labeled
anti-CD25 (Becton Dickinson, San Jose, CA, USA) antibod-
ies, according to the manufacturer’s instructions. After
30 min  of incubation at 4 ◦C in the dark, cells were washed
with Macs buffer, ﬁxed and permeabilized with FoxP3 ﬁxa-
tion/permeabilization buffer (eBioscience, San Diego, CA, USA)
and then processed for FoxP3 staining using the FoxP3 stain-
ing kit and APC-labeled anti-FoxP3 (eBioscience) according to
the manufacturer’s instructions.
Samples were processed on a FACSCanto ﬂow cytometer,
using FACSDIVA software (BD Biosciences), and the acquired
data were analyzed with FLOWJO software (Tree Star, San
Carlo, CA). Fluorescence voltages were determined using
matched unstained cells. Compensation was carried out using
CompBeads (BD Biosciences) single stained with CD3–PerCP,
CD4–FITC, CD8–APC–CY7, CD4–PE–CY7, CD3–PE or CD3–APC,
respectively. Samples were acquired until at least 500,000
events in a live cell gate were obtained.
Data were reported as median and interquartile range
(IQR). Comparisons among groups were carried out using
the Kruskall–Wallis non-parametric test, followed by inter-
group comparisons by the Dunnet test. Correlations were
performed using the Spearman’s non-parametric method.
Statistical inference level was established at 5% (p < 0.05).Results
Decreased  frequency  of  CD4+ T  cells  and  increased
frequency  of  newly  activated  cells  in  SLE
The relative frequency of CD4+ cells over total CD3+ cells in
PBMC cultures stimulated with HEp-2 cell extract was signif-
icantly lower in samples from patients with A-SLE (18.4 ± 8.9)
and I-SLE (17.3 ± 7.6) as compared to controls (24.0 ± 8.2)
(Fig. 1A). Likewise, PBMC cultures stimulated with PMA/Io pre-
sented lower relative frequency of CD4+ cells over total CD3+
cells in samples from patients with A-SLE (16.6 ± 8.4) and I-
SLE (19.6 ± 7.6) as compared to controls (25.3 ± 6.4) (Fig. 1B).
The same was observed for non-stimulated PBMC cultures
(data not shown). In contrast, when we evaluated newly
activated cells, characterized by the expression of the CD69
molecule, higher relative frequency of CD4+CD69+ cells over
total CD4+ cells was observed in patients with A-SLE (5.1 ± 6.6)
and I-SLE (4.9 ± 5.2) when compared to controls (2.8 ± 1.9) in
cultures stimulated with HEp-2 cell extract (Fig. 1C) as well
as with PMA/Io: A-SLE (6.6 ± 8.3), I-SLE (5.9 ± 5.5), and controls
(3.5 ± 2.0) (Fig. 1D). Again, a similar behavior was observed in
non-stimulated PBMC cultures (data not shown).
Multifunctional  proﬁle  of  CD4+ T  cells  in  SLE
Next, we  investigated the functional proﬁle of CD4+ cells
after auto-antigen-speciﬁc (HEp-2 extract) and non-speciﬁc
(PMA/Io) stimuli. This was accomplished by simultaneously
determining intracellular IL-2, IL-17 and INF- by ﬂow cytom-
etry after in vitro stimulation with HEp-2 extract and PMA/Io,
respectively. Fig. 2A shows the gating strategy and the multi-
parametric characterization of mono-, bi-, and tri-functional
response patterns in a representative patient with active SLE.
The frequency of these T cell functional subsets was then
explored in healthy controls and in patients with active and
inactive SLE.
There was increased relative frequency of cells that pro-
duced at least one of the three cytokines analyzed in patients
with A-SLE and I-SLE compared to controls, either when stim-
ulated with HEp-2 (Fig. 2B) or PMA/Io (Fig. 2C), but not in
non-stimulated cultures (data not shown). There was no dif-
ference in the relative frequency of tri-functional cells among
SLE patients and controls in cultures stimulated with HEp-
2 cell extract or PMA/Io (Fig. 2D, Table 2). In addition, there
was no difference in the relative frequency of mono- or bi-
functional cells in cultures from the three groups stimulated
with extract of HEp-2 cell extract or PMA/Io (Fig. 2D, Table 2).
Most bi-functional and mono-functional T cells had similar
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Fig. 1 – Relative frequency of CD4+ T cells in patients with active SLE, inactive SLE and controls (A) and relative frequency of
CD4+CD69+ T cells in patients with active SLE, inactive SLE and controls in stimulation with HEp-2 (A, C) and stimulated
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requency in samples from SLE patients and controls. How-
ver, samples from patients with A-SLE and I-SLE presented
igher frequency of IL-17 producing cells in cultures stimu-
ated with PMA/Io but not in those stimulated with HEp-2 cell
xtract (Fig. 2D and Table 2). In addition, bi-functional cells
roducing IL-17 and INF- showed a strong trend for higher
requency in PMA-stimulated cultures from A-SLE and I-SLE
atients as compared with those from normal controls (Fig. 2D
nd Table 2). As can be appreciated in Fig. 2D, there was a
road variation in the frequency of mono-functional cells in
timulated cultures from SLE patients, with several patients
resenting very high frequency of cells expressing IL-17 and
NF-.
i-functional  IL-2+/INF-+ CD4+ T  cells  produce  more  INF
han mono-functional  INF-+ CD4+ T  cells
ext we asked if the amount of cytokines produced by mul-
ifunctional and mono-functional T cells was equivalent. To
valuate this parameter we assessed the mean ﬂuorescence
ntensity (MFI) for each of the three cytokines evaluated. As
an be seen in experiments with PMA/Io-stimulated samples
rom controls, IFN- MFI  in bi-functional IL-2+/INF-+ cells
as signiﬁcantly higher than in other T cell subpopulations,
ven those that produce only INF- (Fig. 3A and B). This fea-
ure was equally observed in samples from SLE patients and
ontrols (Fig. 3C–E). This phenomenon was not observed in
hose cultures without stimulation or stimulated with HEp-2
ells extracts (data not shown). This behavior was observed
n all 36 SLE patients and 14 healthy volunteers examined.. *p < 0.05; **p < 0.01; ***p  < 0.001.
Such a behavior was not observed for IL-17 and IL-2 in CD4+
T cells in any of the three groups of individuals (data not
shown).
Correlation  between  the  frequency  of  Th17  cells  and  newly
activated  cells  in  patients  with  inactive  SLE
and with  CD4+ T  effector  cells  in  active  SLE
There was a positive correlation between the frequency of
Th17 cells and recently activated cells in PBMC samples from
patients with I-SLE in non-stimulated cultures (Fig. 4A) or
under stimulus with HEp-2 cells extract (Fig. 4B), but not
when cells were stimulated with PMA/Io (Fig. 4C). There was
also a positive correlation between the frequency of Th17
lymphocytes and CD4+CD25+Foxp3∅ cells in samples from
patients with active SLE either without or under different
stimuli (Fig. 4D–F). In control samples, there was also a positive
correlation between the frequency of Th17 and CD25+Foxp3∅
cells when stimulated with HEp-2 cell extract and in non-
stimulated cultures, but not in those stimulated with PMA/Io
(data not shown). There was no such correlation in cultures
of samples from patients with inactive SLE (data not shown).
There was no correlation between the relative frequency of
Th17 cells and Treg cells (CD25highCD127∅Foxp3+) in samples
from controls and patients with SLE independent of the exist-
ence of culture stimulus (data not shown). Finally, there was
no correlation between SLE activity measured by SLEDAI and
the relative frequency of Th17 cells or any other investigated
T lymphocyte subset in stimulated and non-stimulated cul-
tures.
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The purpose of the present study was to evaluate the immune
system of patients with SLE, regarding effector pathways of
CD4+ T cells producing IL-17 (Th17) and multifunctional CD4+
T cells. Therefore, we stimulated PBMC cultures with HEp-
2 cell extract, which expresses most self-antigens of clinical
importance in SLE, including Sm/RNP, SS-A/Ro, and SS-B/La
polypeptides, as well as chromatin antigens. This stimulus
allowed us to evaluate, among the pool of CD4+ T cells, those
with self-reactive capacity, compared to non-stimulated cells
and with cells stimulated with PMA/Io (polyclonal stimula-
tion). These experiments showed that PBMC from SLE patients
did respond to stimulation with auto-antigens. Furthermore,
we observed that even in healthy individuals, there were CD4+T cells sensitive to stimulation with HEp-2 cell-derived self-
antigens, but in smaller proportions compared to patients
with SLE.In this context, we  observed that cultures from patients
with active SLE presented lower relative frequency of CD4+ T
cells, as previously reported by Wouters et al.27 On the other
hand, samples from patients with active and inactive SLE had
an increased frequency of newly activated T cells (CD4+CD69+).
The reduction in CD4+ cell relative frequency may be related
to the immunosuppressant therapy effects, since several of
the studied patients were under immunosuppressant ther-
apy. In contrast, the increased frequency of CD4+CD69+ T cells
possibly corresponds to the fraction of recently activated T
cells that may contribute to the maintenance of exacerbated
autoimmune response and disease activity despite treatment.
There was an increased relative frequency of CD4+ T cells
producing either IL-2, IL-17 or INF- in samples from patients
with A-SLE and I-SLE after stimulus with PMA/Io or HEp-2 cell
extract. The increased proportion of circulating cells able to
assume a phenotype of cytokine secretion after stimulation
indicates that the immune system in SLE patients presents
an expressive pool of partially differentiated cells ready to
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take on effector function. It is possible that this extends to
inﬂammatory sites of target organs, thereby contributing to
the perpetuation of inﬂammation at these sites.
The next step was to evaluate the relative frequency of cells
able to produce each cytokine individually and cells able to
take a multifunctional phenotype by producing more  than one
cytokine. In fact, we found an increased relative frequency of
CD4+ IL-17-producing T cells (Th17 lymphocytes) in PMA/Io-
stimulated cultures from patients with A-SLE and I-SLE. This
ﬁnding corroborates previous reports in the literature, show-
ing an increased frequency of Th17 cells and increased serum
levels of IL-17 in SLE patients.10,15,16,18,28–31 However, we can-
not exclude the participation of Th1 cells and the related
cytokine INF- in the inﬂammatory process of SLE. In fact,
our data show that the frequency of IFN--producing cells
was consistently higher in samples from SLE patients than
in control samples, under PMA/Io or HEp-2 stimulus.
To the best of our knowledge, this is the ﬁrst study assessing
the relative frequency of multifunctional T cells in SLE. This
type of analysis allows a ﬂexible deﬁnition of functional sub-
types of T cells that contrasts with the traditional polarized
classiﬁcation of subtypes deﬁned by surface markers. Based
on this concept we analyzed the multifunctional activity of
CD4+ T cells. There was no difference in the relative frequency
of bi-functional (INF-+/IL-2+; IL-2+/IL-17+; IFN-+/IL-17+) and
tri-functional cells (INF-+ IL-2+ IL-17+) CD4+ cells in patients
with A-SLE, I-SLE and controls. However, when we  analyzed
the frequency of tri-functional cells relative to all cells produc-
ing any one of the analyzed cytokines, we did ﬁnd a signiﬁcant
difference in cultures stimulated with PMA/Io, where samples
from patients with A-SLE had signiﬁcantly higher relative fre-
quency of multifunctional T cells than those from I-SLE. This
ﬁnding suggests that patients with A-SLE show an increased
subpopulation of T helper cells able to produce a broad spec-
trum of pro-inﬂammatory cytokines after a strong stimulus,
such as PMA/Io. This increased subpopulation may contribute
to the immune disorders in SLE autoimmune process. Another
interesting ﬁnding concerning multifunctional T cells was the
observation that CD4+ T cells expressing IL-2 and INF- pro-
duced more  IFN- than did cells that expressed only IFN-.
This was equally observed in samples from patients and con-
trols. An analogous phenomenon has been shown by Betts
et al.,19 who observed an increased production of INF- by
tri-functional cells in HIV-infected patients.
There was a signiﬁcant correlation between the frequency
of Th17 cells and recently activated cells (CD4+CD69+) in
patients with I-SLE as well as a correlation between the
frequency of Th17 cells and CD4+CD25+Foxp3∅ in patients
with A-SLE. These results suggest that IL-17 production is
predominantly associated with recently activated T cells in
inactive-stage SLE and with regular activated effector T cells in
active-stage SLE. This concept is illustrated in Fig. 5. We found
no correlation between SLE activity, measured by SLEDAI, and
the frequency of IL17-producing T cells in patients with A-SLE,
as also observed by Wong et al. (2000). However, other stud-
ies showed signiﬁcant correlation between SLEDAI and Th17
16,29frequency.
The combined analysis of the data herein presented,
together with the existing information in the literature, pro-
vides clues to a better understanding of the pathophysiology of
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SLE and opens perspectives to the development of alternative
therapies for this disease. We  believe that the immunological
pattern observed in the present study occurs in SLE patients in
general, but there is considerable heterogeneity in the group.
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Showing that the majority of cells responsible for production of IL-17 are those newly activated in patients with I-SLE, while
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or T cells will be effective in helping restore the immunologic
alance in each patient. IL-17-producing T lymphocytes seem
o play a prominent role in SLE pathophysiology and may rep-
esent a potential target for therapy. In fact, it is possible that
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